Reviewing Shanghai Junshi Biosciences (OTCMKTS:SHJBF) & ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ:IMGN) and Shanghai Junshi Biosciences (OTCMKTS:SHJBF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Earnings & Valuation

This table compares ImmunoGen and Shanghai Junshi Biosciences’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunoGen	$287.61 million	28.91	-$222.93 million	($0.31)	-100.74
Shanghai Junshi Biosciences	N/A	N/A	N/A	N/A	N/A

Shanghai Junshi Biosciences has lower revenue, but higher earnings than ImmunoGen.

Profitability

This table compares ImmunoGen and Shanghai Junshi Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmunoGen	-25.56%	-22.11%	-13.53%
Shanghai Junshi Biosciences	N/A	N/A	N/A

Insider & Institutional Ownership

90.5% of ImmunoGen shares are owned by institutional investors. 5.1% of ImmunoGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for ImmunoGen and Shanghai Junshi Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunoGen	0	9	3	0	2.25
Shanghai Junshi Biosciences	0	0	0	0	N/A

ImmunoGen presently has a consensus target price of $25.77, suggesting a potential downside of 17.48%. Given ImmunoGen’s higher possible upside, equities analysts clearly believe ImmunoGen is more favorable than Shanghai Junshi Biosciences.

Summary

ImmunoGen beats Shanghai Junshi Biosciences on 5 of the 8 factors compared between the two stocks.

About ImmunoGen

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

About Shanghai Junshi Biosciences

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.